Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers
Authors:
Open Access
- 9 January 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 21 (1) , e1012615
Abstract
Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA. Here, we employed a recently developed multiscale mathematical model describing intra- and intercellular viral propagation and applied it in HBV-infected patients under treatment. We developed a model that can predict intracellular HBV dynamics by use of extracellular viral markers, including HBsAg, HBV DNA, and HBcrAg in peripheral blood. Importantly, the model prediction of the amount of cccDNA in patients over time was confirmed to be well correlated with the data for quantified cccDNA by paired liver biopsy. Thus, our method combining classic and emerging surrogate markers enables us to predict the decay dynamics of cccDNA in patients undergoing treatment.Keywords
Funding Information
- Japan Society for the Promotion of Science (20J00868, 21K15453)
- Scientific Research (KAKENHI) B (18H01139, 16H04845)
- Scientific Research (KAKENHI) B (20H03499, 21H02449)
- Scientific Research in Innovative Areas (20H05042)
- The Ministry of Education, Culture, Sports, Science, and Technology (20K16996)
- AMED Strategic International Brain Science Research Promotion Program (22wm0425011s0302)
- AMED (JP22dm0307009)
- AMED CREST (19gm1310002)
- AMED Development of Vaccines for the Novel Coronavirus Disease (21nf0101638s0201)
- AMED Japan Program for Infectious Diseases Research and Infrastructure (22wm0325007s8002)
- AMED Japan Program for Infectious Diseases Research and Infrastructure (22wm0325007j0103)
- AMED Japan Program for Infectious Diseases Research and Infrastructure (22wm0325007h0001, 22wm0325004s0201, 22wm0325012s0301, 22wm0325015s0301)
- AMED Research Program on Emerging and Re-Emerging Infectious Diseases (21wm0325007s8002)
- AMED Research Program on Emerging and Re-Emerging Infectious Diseases (22fk0108140s0802)
- AMED Research Program on HIV/AIDS (22fk0410052s0401)
- AMED Program for Basic and Clinical Research on Hepatitis (22fk0210094)
- AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B (22fk0310504j0001)
- AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B (22fk0310504h0501)
- AMED International Collaborative Research Program Strategic International Collaborative Research Program (22jm0210068j0004)
- AMED Research Program on Hepatitis (19fk0210036h0502, 19fk0310114h0103)
- AMED Research Program on Hepatitis (19fk0210036j0002, 19fk0310114j0003, 19fk0310103j0203 19fk0310101j1003,)
- AMED Research Program on Hepatitis (JP23fk0310518)
- JST-Mirai Program (JPMJMI22G1)
- JST-Mirai Program (JPMJMI22G1)
- Moonshot Research and Development Program (JPMJMS2021)
- Moonshot Research and Development Program (JPMJMS2021, JPMJMS2025)
- National Research Foundation of Korea (2022R1C1C2003637)
- National Institutes of Health Grants (R01-OD011095, R01-AI078881, R01-AI116868)
- Smoking Research Foundation
- the Takeda Science Foundation
- Taiju Life Social Welfare Foundation
- Shin-Nihon of Advanced Medical Research
- Secom Science and Technology Foundation
- The Japan Prize Foundation
This publication has 72 references indexed in Scilit:
- Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B PatientsHepatology, 2020
- Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus InfectionHepatology, 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Extended duration of treatment with peginterferon alfa‐2a in patients with chronic hepatitis B, HBeAg‐negative and E genotype: A retrospective analysisJournal of Medical Virology, 2018
- Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis BHepatology, 2018
- Hepatitis B cure: From discovery to regulatory approvalHepatology, 2017
- Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis BJournal of Medical Virology, 2014
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #Hepatology, 2009
- Modeling complex decay profiles of hepatitis B virus during antiviral therapy†‡Hepatology, 2008
- Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patientsHepatology, 2006